Local News

• Acucela and Otsuka enter co-development agreement for ACU-4429 in Dry AMD  Acucela and Otsuka Pharmaceutical Co. announced that they have entered into a definitive agreement to co-develop Acucela’s lead compound ACU-4429 which is currently in Phase I clinical development for the dry form of age-related macular degeneration (AMD) in the United States.
  Acucela, Inc. September 04, 2008  
• Acucela and Otsuka Pharmaceutical enter co-development agreement - Rebamipide  Acucela and Otsuka Pharmaceutical Co. announced that they have entered into a definitive agreement to co-develop Rebamipide ophthalmic suspension, Otsuka's proprietary compound for the treatment of dry eye which is currently in Phase III clinical development in the United States.
  Acucela Inc. September 04, 2008  
• Abbott recognized on Dow Jones Sustainability Index (DJSI) for fourth consecutive year  Abbott announced that it was recognized on the Dow Jones Sustainability World Index and the Dow Jones Sustainability North America Index for the fourth consecutive year.
  Abbott September 04, 2008  
• Amgen and Wyeth statement on the FDA Safety Announcement regarding TNF blockers  Amgen and Wyeth Pharmaceuticals issued a statement in response to the Food and Drug Administration (FDA) safety announcement regarding opportunistic fungal infections in patients treated with Tumor Necrosis Factor (TNF) blockers (marketed as Remicade(R), Enbrel(R), Humira(R) and Cimzia(R)).
  Amgen September 04, 2008  
• Percutaneous coronary intervention with CYPHER(R) stent comparable to bypass surgery  Data from the largest randomized trial of its kind performed to date indicate that the use of percutaneous coronary intervention with the CYPHER(R) Sirolimus-eluting Coronary Stent was comparable to bypass surgery in key safety endpoints in patients with multi-vessel disease and diabetes.
  Johnson & Johnson September 04, 2008  
• Monsanto's Roundup Ready 2 Yield(TM) Soybeans receive China regulatory approval  Monsanto Company announced it has received regulatory approval in China for the importation of Roundup Ready 2 Yield(TM) soybeans. China imports accounted for approximately 38 percent of U.S. soybean exports in 2007, making it the largest purchaser of U.S. soybeans.
  Monsanto Company September 04, 2008  
• BioMS Medical's lead MS drug, dirucotide, receives fast track designation from FDA  BioMS Medical announced that the Food and Drug Administration of the United States has granted fast track designation for the Company's lead drug, dirucotide (MBP8298), for the treatment of secondary progressive MS (SPMS).
  BioMS Medical Corp. September 04, 2008  
• MDRNA receives additional funding from National Institutes of Health  MDRNA announced that the National Institutes of Health (NIH) has awarded the Company over $350,000 for further development of the Company's siRNA therapeutics program to prevent and treat influenza.
  MDRNA, Inc. September 04, 2008  
• ViroPharma and Lev receive Hart-Scott-Rodino Clearance from FTC  ViroPharma and Lev Pharmaceuticals announced that the waiting period required under the Hart-Scott-Rodino Antitrust Improvements Act has expired in connection with ViroPharma's proposed acquisition of Lev Pharmaceuticals.
  ViroPharma Inc. September 03, 2008  
• Pfizer and Medivation enter into global agreement to co-develop and market Dimebon  Pfizer and Medivation have entered into an agreement to develop and commercialize Dimebon, Medivation's investigational drug for Alzheimer's disease and Huntington's disease. Dimebon currently is being evaluated in an international, confirmatory Phase III trial.
  Pfizer Inc September 03, 2008  

   (next 10 articles)